– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – “At Gilead, we develop novel antiviral ...
– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback